toxylact

The first professional lActological database in the word

Difenoxin (ATC A07DA04) is a potent opioid antidiarrheal, closely related to diphenoxylate and usually combined with atropine, that reduces intestinal motility for short‑term control of severe diarrhea, but because its lactation safety is unknown and opioid metabolites and atropine can pass into breast milk, it is generally not recommended in breastfeeding and should be avoided in favor of safer alternatives such as loperamide.atcddd.fhi+4

ATC A07DA04 overview

ATC code A07DA04 designates difenoxin within the “Antipropulsives” subgroup, alongside diphenoxylate (A07DA01), opium (A07DA02) and loperamide (A07DA03). Difenoxin is marketed mainly in fixed combination with atropine (for example Motofen), with the ATC code encompassing these combinations as antidiarrheal motility‑reducing agents.atcddd.fhi+5

Pharmacology and mechanism

Difenoxin is a 4‑phenylpiperidine opioid structurally and pharmacologically related to meperidine (pethidine). It slows intestinal motility by acting on opioid receptors in the gastrointestinal tract, thereby increasing transit time, enhancing fluid and electrolyte absorption, and reducing stool frequency and volume—mechanisms typical of antipropulsives. Atropine is added in small doses to discourage overdose and abuse, contributing anticholinergic effects that can further reduce gastrointestinal secretions.drugs+5

Therapeutic indications

Difenoxin/atropine combinations are indicated as adjunct therapy for severe acute nonspecific diarrhea in adults and teenagers, especially when symptomatic control is required in addition to oral rehydration and etiologic treatment. They are not recommended in children and are contraindicated or used with great caution in inflammatory bowel disease (for example severe ulcerative colitis) due to risk of toxic megacolon.mayoclinic+2

Dosage and administration

For severe diarrhea in adults and teenagers, the initial dose is typically 2 mg difenoxin, followed by 1 mg after each loose stool or every 3–4 hours as needed, with a maximum of 8 mg in any 24‑hour period. Treatment should be short‑term; if symptoms do not improve promptly, further evaluation of the underlying cause is required rather than continued dose escalation.drugbank+2

Pharmacokinetics relevant to lactation

Difenoxin is orally absorbed and, like diphenoxylate, is metabolized to active opioid species that contribute to antidiarrheal effects and can reach central compartments. Atropine is known to be excreted into human milk, and by analogy with diphenoxylate’s active metabolite (difenoxylic acid), difenoxin may also be excreted in breast milk, although specific human lactation pharmacokinetic data are lacking.ncbi.nlm.nih+4

Maternal safety and adverse effects

Common adverse effects include constipation, abdominal discomfort, dizziness, drowsiness, nausea, and dry mouth, reflecting both opioid and anticholinergic actions. Serious risks include central nervous system and respiratory depression in overdose, anticholinergic toxicity, and the possibility of toxic megacolon in patients with severe colitis, making thorough clinical assessment essential before use.mayoclinic+1

Lactation safety assessment

Reference sources state that the safety of difenoxin use during lactation is unknown and that it is therefore not recommended for breastfeeding women. Given established breast‑milk transfer of atropine and the potential for opioid metabolites to appear in milk, guidance recommends deciding either to discontinue breastfeeding or to avoid the drug, taking into account the importance of therapy to the mother.ncbi.nlm.nih+4

Potential effects on the breastfed infant

The theoretical infant risks from maternal difenoxin/atropine use include opioid‑related central nervous system and respiratory depression (excessive sleepiness, poor feeding, apnea) and anticholinergic effects (tachycardia, dry mucous membranes, urinary retention). In the absence of reassuring lactation pharmacokinetic data, and given known opioid and atropine passage into milk with diphenoxylate combinations, these risks are considered clinically significant, especially in neonates and preterm infants.ncbi.nlm.nih+4

Practical recommendations in breastfeeding

For breastfeeding women with acute diarrhea, best practice is to continue breastfeeding, use oral rehydration salts, and select antidiarrheals with established lactation safety such as loperamide, which has minimal milk transfer and negligible infant bioavailability. Difenoxin/atropine (A07DA04) should generally be avoided during breastfeeding; if an exceptional scenario arises where its use is judged essential in a mother of an older, full‑term infant, this would require specialist consultation, informed consent, the lowest effective dose for the shortest period, and very close monitoring of the infant for any signs of opioid or anticholinergic toxicity.ncbi.nlm.nih+6

Role within antipropulsives

Among A07DA antipropulsives, difenoxin offers strong antidiarrheal efficacy but presents a less favorable toxico‑lactological profile compared with loperamide, which is peripherally acting and better characterized in breastfeeding. In a lactation‑aware antidiarrheal strategy, difenoxin is therefore a non‑preferred agent reserved for non‑lactating adults with severe diarrhea when other safer options are unsuitable, rather than a routine choice in breastfeeding women.pubmed.ncbi.nlm.nih+4

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.